A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany

Deucravacitinib in Routine Clinical Practice: A 5-year, Multicenter, Prospective, Non-Interventional Cohort Study to Evaluate Effectiveness and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis in Germany (DELPHIN)

The purpose of this observational study is to describe the effectiveness of deucravacitinib treatment and quality of life in adults with moderate-to-severe plaque psoriasis in routine clinical practice in Germany over a 5-year period

Inclusion Criteria:

• Patients with a physician-reported diagnosis of moderate-to-severe plaque psoriasis initiating deucravacitinib according to approved label in the European Union
• The decision upon treatment with deucravacitinib must have been made before enrollment and independently of this non-interventional observational study
• Patient is at least 18 years of age at the time of treatment decision
• Patient provided written informed consent to participate in the study

Exclusion Criteria:

• Any contraindications according to the approved deucravacitinib Summary of Product Characteristics
• Prior treatment with deucravacitinib
• Simultaneous participation in an interventional clinical trial for moderate-to-severe psoriasis